AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11932303
Drug: Longitudinal open-label
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longitudinal open-label pegvisomant treatment
Trial: 9804648
Drug: Remacemide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide (up to 150 mg every 6 hours)
Trial: 7752668
Drug: β-blockers (e.g.,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blockers (e.g., bisoprolol)
Trial: 7752668
Drug: β-blockers (post-MI)
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blockers (post-MI)
Trial: 31047298
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab therapy (monthly or pro re nata)
Trial: 27832073
Drug: 25 μmoles
RxNorm normalized name: Polyacrylamide (crosslinked; 2 mole percent bisacrylamide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μmoles sulforaphane daily for four weeks
Trial: 27832073
Drug: 150 μmoles
RxNorm normalized name: Polyacrylamide (crosslinked; 2 mole percent bisacrylamide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 μmoles sulforaphane daily for four weeks
Trial: 22050496
Drug: lornoxicam (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lornoxicam (group L, n=32 patients)
Trial: 22050496
Drug: paracetamol (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paracetamol (group P, n=31 patients)
Trial: 27165280
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg
Trial: 7947240
Drug: rHuEPO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO treatment
Trial: 11426506
Drug: Crossover treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover treatment (alternate medication)
Trial: 9470828
Drug: PCI 36
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI 36 Gy in 18 daily fractions
Trial: 9470828
Drug: PCI (most
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI (most commonly used regimens: 30 Gy in 10 fractions and 8 Gy in a single dose)
Trial: 31765263
Drug: Nivolumab, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab, 3 mg/kg every 2 weeks for the first 4 cycles, then 480 mg every 4 weeks after cycle 4, administered intravenously.
Trial: 20936979
Drug: Accelerated vaccination
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated vaccination schedule (vaccines at 0, 1, and 2 months)
Trial: 20936979
Drug: Standard vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard vaccination schedule (vaccines at 0, 1, and 6 months)
Trial: 20936979
Drug: Overall drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall drug users on accelerated schedule
Trial: 20936979
Drug: Overall drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall drug users on standard schedule
Trial: 18760649
Drug: 16 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 Gy boost dose after complete lumpectomy
Trial: 18760649
Drug: 0 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 Gy boost dose after complete lumpectomy
Trial: 18760649
Drug: 26 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26 Gy boost dose after incomplete lumpectomy
Trial: 18760649
Drug: 10 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 Gy boost dose after incomplete lumpectomy
Trial: 29980320
Drug: 16 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 Gy boost dose
Trial: 18760649
Drug: 10 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 Gy boost dose
Trial: 18760649
Drug: 0 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 Gy boost dose
Trial: 29980320
Drug: 26 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26 Gy boost dose
Trial: 15701299
Drug: Maintenance interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance interferon therapy
Trial: 10066694
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (4 x 5 g/day)
Trial: 8721127
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg buprenorphine suppository (BN)
Trial: 8721127
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg buprenorphine suppository (BN) and 50 mg indomethacine suppository (IND)
Trial: 8721127
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg buprenorphine suppository (BN) and 50 mg diclofenac suppository
Trial: 8721127
Drug: No suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No suppository (control group)
Trial: 1867231
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and calcium antagonists
Trial: 7066141
Drug: Neostigmine 2.5
RxNorm normalized name: neostigmine 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 2.5 mg/70 kg
Trial: 27580060
Drug: Non nucleoside
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non nucleoside reverse transcription inhibitor-based ART
Trial: 17320241
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied 1% naltrexone cream for 2 weeks in the open study.
Trial: 17320241
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied 1% naltrexone cream in the placebo-controlled crossover trial.
Trial: 17320241
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream in the placebo-controlled crossover trial.
Trial: 15227556
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Web and fax-based RDE systems
Trial: 8141110
Drug: Control (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (all treatments)
Trial: 23847109
Drug: Glycerol phenylbutyrate
RxNorm normalized name: Glycerol Phenylbutyrate
DrugBank: Glycerol phenylbutyrate (DB08909)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Glycerol phenylbutyrate (GPB) at 6 mL orally twice-daily
Trial: 20888580
Drug: Ghrelin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin (50 μg)
Trial: 18567539
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral doxycycline once per day for 14 days
Trial: 18567539
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g intravenous ceftriaxone once per day for 14 days
Trial: 18567539
Drug: Side effects
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side effects possibly related to treatment in doxycycline group
Trial: 18567539
Drug: Side effects
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side effects possibly related to treatment in ceftriaxone group
Trial: 12053584
Drug: Anti-CD80 monoclonal
RxNorm normalized name: Anti-CD80 monoclonal antibody
DrugBank: Galiximab (DB04901)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD80 monoclonal antibodies
Trial: 12053584
Drug: Anti-CD86 monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CD86 monoclonal antibodies
Trial: 8697157
Drug: 1.25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 g of ethanol per kilogram of body weight diluted to 15% in juice
Trial: 6604940
Drug: Ketoprofen capsules
RxNorm normalized name: Ketoprofen Capsules
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen capsules
Trial: 6604940
Drug: Biovail capsules
RxNorm normalized name: BiovaxID
DrugBank: Dasiprotimut-T (DB17287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biovail capsules
Trial: 6604940
Drug: IBP tablets
RxNorm normalized name: IBP-1118
DrugBank: IBP-1118 (DB18461)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBP tablets
Trial: 30695089
Drug: Conical interface
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conical interface (CI) implants
Trial: 30695089
Drug: Flat-to-flat interface
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flat-to-flat interface (FI) implants
Trial: 30695089
Drug: Platform-switched interface
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-switched interface (PS) implants
Trial: 28169430
Drug: Bendamustine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine 80 mg/m², days 1, 2; Bortezomib 1.3 mg/m², days 1, 8, 15; Dexamethasone 20 mg, days 1, 2, 8, 9, 15, 16 every 28 days (up to 8 cycles), then maintenance 1.3 mg/m² IV bortezomib every 2 weeks
Trial: 28169430
Drug: Original regimen:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original regimen: Bendamustine 80 mg/m², days 1, 4; Bortezomib 1.3 mg/m², days 1, 4, 8, 11; Dexamethasone 40 mg, days 1, 2, 3, 4 on a 28-day cycle (up to 8 cycles)
Trial: 12809960
Drug: Fluvastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 80 mg/d
Trial: 27075710
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg once daily for 7 days)
Trial: 25192562
Drug: 3% concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% concentration cream composed of marjoram, black pepper, lavender, and peppermint
Trial: 25192562
Drug: Unscented cream
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unscented cream
Trial: 12373475
Drug: Early surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early surfactant administration
Trial: 11040233
Drug: Enalaprilat (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat (ACE inhibitor)
Trial: 4946956
Drug: Bacteriophage preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacteriophage preparation (10^8 to 10^9 pfu/ml), given by mouth (25 ml for adults, 20 ml for children) for 3 days, with some receiving an intramuscular injection (20 ml) on the first day.
Trial: 25867448
Drug: Self-system therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-system therapy (SST)
Trial: 24787916
Drug: Treatment-as-usual (waitlist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (waitlist control) for seven weeks
Trial: 20851726
Drug: Food liking
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food liking ratings for chocolate bar, muffin, banana, cola, cornflakes, potato chips, hot chocolate drink, and ice-cream
Trial: 20851726
Drug: Familiarity ratings
RxNorm normalized name: Aratinga erythrogenys feather extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Familiarity ratings for chocolate bar, muffin, banana, cola, cornflakes, potato chips, hot chocolate drink, and ice-cream
Trial: 20851726
Drug: Expected satiation
RxNorm normalized name: docosahexaenoic acid Oral Capsule [Expecta]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expected satiation (ES) ratings for chocolate bar, muffin, banana, cola, cornflakes, potato chips, hot chocolate drink, and ice-cream
Trial: 15608836
Drug: Spironolactone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (50 mg orally twice a day for 6 months)
Trial: 15608836
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral placebo twice a day for 6 months)
Trial: 9639501
Drug: G‐CSF +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF + epo (arm A: G‐CSF for 4 weeks followed by combination for 12 weeks; arm B: epo for 8 weeks followed by combination for 10 weeks)
Trial: 9639501
Drug: Long-term maintenance
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term maintenance treatment
Trial: 28213750
Drug: High EPA
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High EPA fish oil (750 mg EPA, 50 mg DHA)
Trial: 28213750
Drug: Low EPA
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low EPA fish oil (150 mg EPA, 100 mg DHA)
Trial: 21547610
Drug: Medication intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication intensification for hyperglycemia
Trial: 21547610
Drug: Medication intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication intensification for hyperlipidemia
Trial: 21547610
Drug: Medication intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication intensification for hypertension
Trial: 21547610
Drug: Medication intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication intensification for any risk factor
Trial: 18469260
Drug: Formulas containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulas containing Bifidobacterium longum BL999 + Lactobacillus rhamnosus LPR + 4 g/L GOS/SCFOS
Trial: 18469260
Drug: Formulas containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulas containing Bifidobacterium longum BL999 + Lactobacillus paracasei ST11 + 4 g/L GOS/SCFOS
Trial: 17319473
Drug: Lovastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20 mg) and Niacin(ER) (500 mg) combination once daily, with dose escalation to Niacin(ER) (1000 mg) in 11 patients based on lipid parameters at 8 weeks.
Trial: 10599912
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (no barrier placement, vehicle PGA gel used as placebo)
Trial: 1911016
Drug: Labetalol (0.15‐0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (0.15‐0.3 mg kg‐1)
Trial: 6211999
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg alcuronium
Trial: 6211999
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg pancuronium
Trial: 6211999
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg bw Sch
Trial: 6211999
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg bw lignocaine
Trial: 26099755
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia with adjunctive intrathecal morphine (0.1 mg)
Trial: 24732169
Drug: Mixed Kinesio
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed Kinesio taping-compression treatment, performed 3 times a week for 4 weeks
Trial: 11454733
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of [(14)C]linezolid 500 mg (100-microCi)
Trial: 11454733
Drug: 10-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-day regimen of unlabeled linezolid 500 mg b.i.d.
Trial: 11454733
Drug: Single radioactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single radioactive dose of linezolid
Trial: 7525901
Drug: Intra-arterial injection
RxNorm normalized name: METHOTREXATE 25 mg in 1 mL INTRA-ARTERIAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-arterial injection of 131I-iodized oil (Treated group)
Trial: 30014184
Drug: EG-1962 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EG-1962 (600 mg)
Trial: 25678453
Drug: Oral nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nimodipine (active control)
Trial: 15587331
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral hyperalimentation (TPN)
Trial: 8101150
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg ondansetron
Trial: 8101150
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg ondansetron
Trial: 2873161
Drug: Terfenadine suspension
RxNorm normalized name: terfenadine Oral Suspension
DrugBank: Terfenadine (DB00342)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terfenadine suspension (30 mg twice daily for children <30 kg; 60 mg twice daily for children >30 kg)
Trial: 2873161
Drug: Terfenadine suspension
RxNorm normalized name: terfenadine Oral Suspension
DrugBank: Terfenadine (DB00342)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terfenadine suspension
Trial: 30656507
Drug: Model 3
RxNorm normalized name: Model 2004FAA Model 3-EEMK Model 3-EEMK-1 Model AA-8565 Model AA-8565-LATAM Model AWFAREMK Model CHAUTAUQUAEMK Model emk1000-10 Model FAREMK Model PMONTFAREMK Model SWEEMK Model SWEEMK-1 Model QXEMK Model G4FAREMK Model AA-8565 (excluding Miami Air) KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model 3 (combination of Models 1 and 2)
Trial: 29099102
Drug: Melatonin (MEL)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin (MEL) at doses of 25 mg orally every 12 hours for 12 months
Trial: 23537970
Drug: Abciximab plus
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab plus heparin
Trial: 19785815
Drug: Metformin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin as a monotherapy
Trial: 19785815
Drug: Glibenclamide as
RxNorm normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glibenclamide as a monotherapy
Trial: 16716847
Drug: Twelve Steps
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twelve Steps (TS) treatment
Trial: 15525622
Drug: Gargling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gargling with povidone-iodine (2.5 mg/mL, 25 mL)
Trial: 15525622
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (gargling with tap water, 25 mL)
Trial: 9428831
Drug: Metformin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2 x 850 mg/day)
Trial: 7836511
Drug: Control cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control cycle (no treatment)
Trial: 30150504
Drug: One-stage full-mouth
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage full-mouth oral disinfection (FMD)
Trial: 22057852
Drug: Panobinostat 20
RxNorm normalized name: panobinostat 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat 20 mg twice weekly (fasting)
Trial: 22057852
Drug: Panobinostat 20
RxNorm normalized name: panobinostat 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat 20 mg twice weekly (high-fat breakfast)
Trial: 22057852
Drug: Panobinostat 20
RxNorm normalized name: panobinostat 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat 20 mg twice weekly (normal breakfast)
Trial: 22057852
Drug: Panobinostat (overall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat (overall treatment)
Trial: 15924807
Drug: atenolol +
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atenolol + nitrendipine + metformin (A + N + M, n = 152)
Trial: 2299213
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza vaccines with increasing antigen concentrations
Trial: 7027780
Drug: High nutrition
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High nutrition supplement (800 kcal and 40 g of protein/day)
Trial: 7027780
Drug: Low nutrition
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low nutrition supplement (80 kcal/day)
Trial: 31017305
Drug: Audit and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audit and feedback intervention aimed at primary care centers, involving structured quality reports on medication use and diagnosis recording, sent in 2015.
Trial: 29529508
Drug: Dialectical Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behaviour Therapy (DBT) skills training
Trial: 26881973
Drug: Diuretic renogram
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic renogram in volatile substance abusers
Trial: 22247115
Drug: Probiotics and
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics and organic acids (1 g/L in water) including Lactobacillus acidophilus, Lactobacillus casei, Streptococcus faecium, Saccharomyces cerevisiae, 1% sorbic acid, and 0.2% citric acid for 7 days (T2)